SG Americas Securities LLC Cuts Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

SG Americas Securities LLC reduced its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 64.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 70,917 shares of the biotechnology company’s stock after selling 127,269 shares during the quarter. SG Americas Securities LLC’s holdings in Heron Therapeutics were worth $141,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in Heron Therapeutics in the second quarter valued at $27,000. Headlands Technologies LLC acquired a new stake in shares of Heron Therapeutics during the 1st quarter valued at about $30,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Heron Therapeutics in the 1st quarter valued at about $32,000. HB Wealth Management LLC acquired a new position in Heron Therapeutics in the 2nd quarter worth about $35,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Heron Therapeutics in the 2nd quarter worth about $41,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Heron Therapeutics in a report on Wednesday, September 25th.

Heron Therapeutics Stock Up 3.9 %

HRTX opened at $1.85 on Friday. The firm’s fifty day simple moving average is $1.90 and its two-hundred day simple moving average is $2.62. Heron Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $3.93. The company has a market cap of $278.71 million, a price-to-earnings ratio of -3.03 and a beta of 1.80.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same quarter in the previous year, the company earned ($0.35) earnings per share. On average, research analysts forecast that Heron Therapeutics, Inc. will post -0.1 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.